95 related articles for article (PubMed ID: 9168922)
1. Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins.
Holmes G; Boterashvili S; English M; Wainwright B; Licht J; Little M
Biochem Biophys Res Commun; 1997 Apr; 233(3):723-8. PubMed ID: 9168922
[TBL] [Abstract][Full Text] [Related]
2. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
3. WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein.
Wang ZY; Qiu QQ; Gurrieri M; Huang J; Deuel TF
Oncogene; 1995 Mar; 10(6):1243-7. PubMed ID: 7700651
[TBL] [Abstract][Full Text] [Related]
4. Exon 9 mutations in the WT1 gene, without influencing KTS splice isoforms, are also responsible for Frasier syndrome.
Kohsaka T; Tagawa M; Takekoshi Y; Yanagisawa H; Tadokoro K; Yamada M
Hum Mutat; 1999; 14(6):466-70. PubMed ID: 10571943
[TBL] [Abstract][Full Text] [Related]
5. WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion.
Bardeesy N; Zabel B; Schmitt K; Pelletier J
Genomics; 1994 Jun; 21(3):663-4. PubMed ID: 7959750
[No Abstract] [Full Text] [Related]
6. Donor splice-site mutations in WT1 are responsible for Frasier syndrome.
Barbaux S; Niaudet P; Gubler MC; Grünfeld JP; Jaubert F; Kuttenn F; Fékété CN; Souleyreau-Therville N; Thibaud E; Fellous M; McElreavey K
Nat Genet; 1997 Dec; 17(4):467-70. PubMed ID: 9398852
[TBL] [Abstract][Full Text] [Related]
7. Regulation of insulin-like growth factor I receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor.
Tajinda K; Carroll J; Roberts CT
Endocrinology; 1999 Oct; 140(10):4713-24. PubMed ID: 10499530
[TBL] [Abstract][Full Text] [Related]
8. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
Oncogene; 2002 May; 21(19):2948-60. PubMed ID: 12082525
[TBL] [Abstract][Full Text] [Related]
9. Diaphragmatic hernia in Denys-Drash syndrome.
Devriendt K; Deloof E; Moerman P; Legius E; Vanhole C; de Zegher F; Proesmans W; Devlieger H
Am J Med Genet; 1995 May; 57(1):97-101. PubMed ID: 7645607
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain.
Sakamoto Y; Yoshida M; Semba K; Hunter T
Oncogene; 1997 Oct; 15(17):2001-12. PubMed ID: 9366517
[TBL] [Abstract][Full Text] [Related]
11. The DNA binding domains of the WT1 tumor suppressor gene product and chimeric EWS/WT1 oncoprotein are functionally distinct.
Kim J; Lee K; Pelletier J
Oncogene; 1998 Feb; 16(8):1021-30. PubMed ID: 9519876
[TBL] [Abstract][Full Text] [Related]
12. Wilms tumor and the WT1 gene.
Lee SB; Haber DA
Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
[TBL] [Abstract][Full Text] [Related]
13. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.
Patek CE; Fleming S; Miles CG; Bellamy CO; Ladomery M; Spraggon L; Mullins J; Hastie ND; Hooper ML
Hum Mol Genet; 2003 Sep; 12(18):2379-94. PubMed ID: 12915483
[TBL] [Abstract][Full Text] [Related]
14. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
[TBL] [Abstract][Full Text] [Related]
15. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X.
Heathcott RW; Morison IM; Gubler MC; Corbett R; Reeve AE
Hum Mutat; 2002 Apr; 19(4):462. PubMed ID: 11933209
[TBL] [Abstract][Full Text] [Related]
16. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations.
Little M; Holmes G; Bickmore W; van Heyningen V; Hastie N; Wainwright B
Hum Mol Genet; 1995 Mar; 4(3):351-8. PubMed ID: 7795587
[TBL] [Abstract][Full Text] [Related]
17. Atypical presentation of Denys-Drash syndrome in a female with a novel Wt1 gene mutation.
Machin GA
Birth Defects Orig Artic Ser; 1996; 30(1):269-86. PubMed ID: 9125334
[No Abstract] [Full Text] [Related]
18. Role of Wilms tumor 1 (WT1) in the transcriptional regulation of the Mullerian-inhibiting substance promoter.
Hossain A; Saunders GF
Biol Reprod; 2003 Dec; 69(6):1808-14. PubMed ID: 12855602
[TBL] [Abstract][Full Text] [Related]
19. Analysis of WT1 target gene expression in stably transfected cell lines.
Thäte C; Englert C; Gessler M
Oncogene; 1998 Sep; 17(10):1287-94. PubMed ID: 9771972
[TBL] [Abstract][Full Text] [Related]
20. Physical and functional interaction between the HCMV IE2 protein and the Wilms' tumor suppressor WT1.
Kim JM; Hong Y; Semba K; Kim S
Biochem Biophys Res Commun; 2000 Jan; 267(1):59-63. PubMed ID: 10623574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
